Who Paid My Doc
A Phase 3B Randomized Study of Lenalidomide (CC-50
Research payments
$860,326
Through program year 2022, $860,326 in research payments was reported against A Phase 3B Randomized Study of Lenalidomide (CC-50, across 74 payments, paid by Celgene Corporation.
- Paid by
- Celgene Corporation
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $475,357 | 23 |
| 2021 | Research | $384,969 | 51 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Christopher Reynolds Ypsilanti, MI Named on 3 payments
- Frederick Lansigan Lebanon, NH Named on 3 payments
- Morton Coleman New York, NY Named on 3 payments
- Timothy Wassenaar Waukesha, WI Named on 3 payments
- Stephen Mayer Glenwood Springs, CO Named on 3 payments
- Vinod Parameswaran Sioux Falls, SD Named on 3 payments
- Jay Courtright Dallas, TX Named on 3 payments
- Stephan Kendall Salt Lake City, UT Named on 2 payments
- Grzegorz Nowakowski Rochester, MN Named on 2 payments
- Gordon Srkalovic Lansing, MI Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.